News
Public · Published
Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting
Moleculin said an abstract reporting the first interim results from its pivotal Phase 2/3 trial of Annamycin plus cytarabine in relapsed or refractory acute myeloid leukemia was accepted for presentation at the 2026 ASH meeting. Among 45 patients, remission rates were 43% and 36% in the two treatment arms, versus 12% with placebo.
Published:
Updated:
What happened
Moleculin said an abstract reporting the first interim results from its pivotal Phase 2/3 trial of Annamycin plus cytarabine in relapsed or refractory acute myeloid leukemia was accepted for presentation at the 2026 ASH meeting. Among 45 patients, remission rates were 43% and 36% in the two treatment arms, versus 12% with placebo.
Confirmed
Global impact / market context
The reported remission difference could support Annamycin’s development if later analyses confirm it, potentially improving its commercial prospects and Moleculin’s future revenue options. However, this is interim evidence from a limited group, and the report says cardiac safety data still require independent review.
Analyst inference
Acceptance for a medical meeting gives the company a forum to present clinical findings, but does not establish that the treatment works or will be approved. For investors, the central issue is whether further trial analysis supports the remission results and acceptable safety.
Analyst inference
What to watch
- The accepted abstract is scheduled for presentation at the ASH annual meeting in New Orleans from December 12 to 15, 2026. Confirmed
- The second interim analysis is expected to include independent expert and Data Monitoring Committee review of all cardiac safety data, according to the article. Confirmed
- Watch for fuller trial results and safety conclusions: stronger evidence could improve development prospects, while weaker results or safety concerns could reduce expected commercial value. Analyst inference